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Topical Dangers
Although topical corticosteroids 
are prescribed to more than 6% 
of pregnant women, conflicting 
evidence has prevented 
accurate safety assessment of 
this drug. Chi and colleagues 
used the UK General Practice 
Research Database to perform 
a population-based cohort 
study aimed at determining 
whether maternal exposure to 
topical corticosteroids leads to 
adverse pregnancy outcomes. A 
significant association between 
fetal growth restriction and 
maternal exposure to potent/
very potent topical steroids 
was identified; however, no 
increases in orofacial cleft, 
preterm delivery, miscarriage, 
or stillbirths upon exposure to 
topical corticosteroids were 
found, suggesting that topical 
corticosteroids may be a safe 
option in treating inflammatory 
or autoimmune bullous 
dermatoses during pregnancy. 
See page 884
Novel Marker for 
Sézary Syndrome
Identification of specific 
markers for cells from patients 
with Sézary syndrome 
(SS), an aggressive form of 
T-cell lymphoma, has been 
challenging. Bensussan and 
colleagues identified the natural 
cytotoxicity receptor NKp46 
specifically on circulating 
malignant CD4+ T lymphocytes 
from SS patients but not on 
normal circulating CD4+ T cells. 
NKp46 engagement did not 
induce tyrosine phosphorylation 
of CD3ζ but instead inhibited 
CD3-mediated activation 
and proliferation of these 
cells. Importantly, NKp46 may 
represent a novel diagnostic 
marker for SS. See page 969
Personalized Treatment for RDEB
The recently identified induced pluripotent 
stem (iPS) cells offer an opportunity to uti-
lize gene-corrected autologous cells for the 
systemic treatment of recessive dystrophic 
epiderm olysis bullosa (RDEB). Indeed, Tolar 
and colleagues isolated iPS cells from skin 
fibroblasts and keratinocytes from RDEB 
patients, and these cells were able to dif-
ferentiate into both hematopoietic and non-
hematopoietic cell lineages. These iPS cells 
formed skin-like structures in vitro, providing 
a robust system for studying skin pathology in a patient-specific manner. Furthermore, 
transfection of the COL7 gene allowed these cells to express wild-type collagen VII, 
underscoring the potential of this cell population for patient-specific stem cell therapy. 
See page 848
Higher RANK
In prostate, breast, and renal cancers, 
interactions between the receptor acti-
vator of nuclear factor-κB (RANK) and 
its ligand (RANKL) have been found to 
be critical for metastasis formation. In 
accord with these findings, Kupas and 
colleagues demonstrated upregulated 
RANK expression as well as increased 
numbers of melanoma cells expressing RANK in the peripheral blood from metastatic 
melanoma (MM) stage IV patients. RANK-expressing melanocyte-specific melanoma 
cells exhibited a tumor stem cell–like phenotype. Therefore, RANK expression may be 
important for the maintenance of melanoma-initiating cells and ultimately for metastasis 
formation and disease spread in MM. See page 944
Slow and Low
Photodynamic therapy (PDT) with the photo-
sensitizers 5-aminolevulinic acid (ALA) or 
methylaminolevulinate (MAL) is increasingly 
used to treat basal cell carcinoma, Bowen’s 
disease, and premalignant actinic keratoses. 
Frost and colleagues found that PDT deliv-
ered at 78 mWcm−2, a value well below 
the maximum recommended fluence rate, 
is highly immunosuppressive in humans, 
whereas PDT at low fluence rates (15 
mWcm−2) is not. Immunosuppression may 
hamper the efficiency of PDT. Furthermore, 
ALA/MAL-PDT at high fluence rates, but not at low fluence rates, induced the genera-
tion of an oxidative photoproduct 8oxoG, which is a marker of DNA damage. Thus, 
PDT-induced immunosuppression in the skin of human volunteers can be prevented by 
merely reducing the rate of light delivery. See page 962
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